⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

SUNPHARMA - Swing Trade Analysis with AI Signals

← Back to List

⭐ Rating: 4.2

Last Updated Time : 19 Sept 26, 07:44 am

Key Parameters

⭐ Swing Trade Rating: 4.2

RSI37.2
MACD-21.0
DMA 501,896 ₹
DMA 2001,824 ₹
Volume29,19,052
Avg Vol 1Wk18,96,041
High / Low2,048 ₹
52w Index57.6 %
Show all parameters (20 more)
Stock CodeSUNPHARMA
Market Cap4,40,705 Cr.
Current Price1,836 ₹
Stock P/E138
Book Value93.2 ₹
Dividend Yield0.87 %
ROCE14.8 %
ROE12.7 %
Face Value1.00 ₹
Chg in FII Hold-1.40 %
Chg in DII Hold1.06 %
PAT Qtr1,139 Cr.
PAT Prev Qtr609 Cr.
Low price1,547 ₹
High price2,048 ₹
PEG Ratio-32.4
Debt to equity0.61
Qtr Profit Var22.8 %
EPS12.5 ₹
Industry PE34.8

🧾 Trade Setup

Entry Price: 1805 ₹. Target Exit Level 1875₹ – A stop-loss order can be placed at 1800₹, aiming for a profit target of around 1875₹ within the next 3-5 days based on the current momentum and RSI signal. This represents a relatively conservative swing trade with manageable risk given the strong earnings performance. Overall, SUNPHARMA presents a compelling opportunity for short to medium-term gains but requires diligent monitoring for any sign of reversal.

✅ Positive

The recent PAT growth of 22.8% and a substantial increase in quarterly profits (1,139 Cr vs 609 Cr) demonstrate significant near-term momentum. Furthermore, the RSI reading of 37.2 indicates the stock is currently undervalued relative to its historical levels and suggests potential for an upward price correction.

⚠️ Limitation

Despite strong recent earnings, the Stock P/E ratio of 138 remains exceptionally high compared to the industry average of 34.8, indicating a premium valuation which presents a considerable risk if momentum fades. The substantial debt-to-equity ratio of 0.61 also warrants attention as it could constrain future growth opportunities and potentially impact shareholder returns.

🏭 Industry

The pharmaceutical sector is currently experiencing moderate bullish sentiment driven by innovation in drug development and regulatory approvals, though concerns regarding generic drug pricing pressures remain a persistent factor for many players; recent gains in Taro Pharmaceutical’s stock price due to the merger offer provide further tailwinds.

Choose Technical Analysis or Fundamental Analysis above to load it.

How SUNPHARMA Rates Across All Strategies

Swing Trade
★ 4.2
You're viewing this analysis below.
★ 2.5
Buy Price: 1,850 ₹.
★ 3.2
An entry price zone between 1,650 ₹ and 1,750 ₹ represents a reasonab…
★ 3.2
Short-term entry zones could be established between 1,800 ₹ (support…
★ 2.3
We recommend an entry zone around 1,700 ₹ based on the current underv…

NIFTY 50 · Swing Trading

NEXT 50 · Swing Trading

MIDCAP · Swing Trading

SMALLCAP · Swing Trading